The last day of 2012
DAC Biotech was founded in Hangzhou.
2013
Established a R&D center
2014
One of the first batch of Leading Entrepreneurial Innovation Teams in Zhejiang Province
2015
Second place in the nation-wide Innovation and Entrepreneurship Competition in China
Round Pre-A financing
2016
Built the first pilot production line
2017
Round A financing
2018
The project of DAC-002 was selected as a Major Technological Innovation Project in Hangzhou.
2019
Round Bfinancing
Clinical trial of DX126-262 initiated
The project of DX126-262 was selected as a National Major Technological Innovation Project
2020
Built the second pilot production lineDAC-002 was approved by NMPA to enter clinical trials
Formed a strategic partnership with Shanghai Junshi Biosciences Clinical trial of DAC-002 initiated by Junshi Biosciences with drugs produced in DAC Biotechnology.
2021
Round C financing;
DX126-262 was approved by FAD to proceed clinical studies in the US Initiate multi-center phase II clinical trials of DX126-262 in several countries;
DXC-005 was approved by NMPA to enter clinical trials, began clinical trials of DXC-005
2023
Expected moving into our new R&D and Production facilities, and further expanding the company’s research, development and manufacture capacity.
